Compare Johnson & Johnson (JNJ) vs Vanguard International High Dividend Yield ETF (VYMI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs Vanguard International High Dividend Yield ETF — how do they compare? Johnson & Johnson trades at $260.72 (market cap $618.09B), while Vanguard International High Dividend Yield ETF trades at $100.61 (market cap $22.80B). The key difference: Johnson & Johnson is far larger — about 27.1× Vanguard International High Dividend Yield ETF's market cap, and Johnson & Johnson pays a 2.09% dividend while Vanguard International High Dividend Yield ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Johnson & Johnson for 129 Days and Vanguard International High Dividend Yield ETF for 50 Days on average.
| JNJ | VYMI | |
|---|---|---|
Market Cap | $618.09B | $22.80B |
Volume | 6,050,983 | 748,441 |
Sector | Health | Broad Market / Factor |
52-Week High | $278.43 | $107.13 |
52-Week Low | $186.00 | $82.92 |
Typical Hold Time | 129 Days | 50 Days |
Enterprise Value | $646.37B | — |
Dividend Yield | 2.09% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $259.62, up 0.45% with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with 21.48% net margin and 25.74% ROE, though valuation ratios appear elevated with P/E at 29.75. Recent news highlights growth in the Innovative Medicine segment and positive analyst coverage with 52.5% buy ratings.
JNJ offers stable dividend income and pharmaceutical innovation upside, but faces patent cliff risks and increasing debt-to-asset ratio (24.06% in 2025). Analyst consensus target of $286.53 suggests 10% upside potential, though technical resistance at $260 may limit near-term gains.
VYMI trades at $100.53 with a slight 0.3% daily gain, though technical indicators signal bearish momentum with moving averages showing 11 sell signals versus 2 buy signals. The ETF's recent performance includes a 29% one-year return and 14.13% five-year average annual return, with strong institutional interest as firms like Envestnet increased holdings by 22% in Q2 2026. A dividend of $0.82 is scheduled for payment on September 22, 2026.
The outlook for VYMI is mixed; bullish sentiment from Seeking Alpha highlights sector catalysts in financials, energy, and healthcare supporting dividend growth, while technical bearishness and Fed rate hike impacts pose risks. Investors may find value in its 3.61% dividend yield and global diversification, but should monitor financials exposure (43.6% of holdings) amid rising rates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About Vanguard International High Dividend Yield ETF
VYMI is an index-based ETF that provides exposure to non-U.S. companies across developed and emerging markets that are characterized by high dividend yields. It tracks the FTSE All-World ex US High Dividend Yield Index, offering a diversified, low-cost way to capture international income while serving as a tactical hedge against U.S. market concentration.
Read more on VYMI →
